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AIDS EPIDEMIOLOGY 
HIV infection has been a major cause of 
morbidity and mortality since the first cases of 
AIDS among children were reported in 1982 in 
the United States. In 1997, HIV infection was the 
11th leading cause of death among children 1 to 4 
years of age. Perinatal transmission of HIV 
accounts for 90% of pediatirc AIDS cases and 
almost all new HIV infections in children. An 
estimated 6000 to 7000 infants were born to HIV-
infected women each year from 1989 to 1995, and 
more than 16,000 perinatally HIV-infected 
children have been born since the beginning of the 
epidemic. Considerable advances, especially in 
the past 5 years, in the understanding of the 
pathogenesis, diagnosis, treatment, monitoring, 
and prevention of HIV infection in children have 
changed the epidemiology of pediatric HIV 
infection 1. 
The Second International Conference on 
Global Strategies for the Prevention of HIV 
Transmission from Mothers to Infants held in 
Montreal Canada, September 1999, focused on 
those who suffered mainly i.e. women and 
children. They comprise now almost 50% of those 
who are infected with HIV. They are more easily 
infected, have little or no control over the 
circumstances under which they become infected, 
progress to disease more rapidly, have poorer 
health care, benefit from treatment more slowly, 
and suffer some of the severest consequences of 
discrimination. A diagnosis of HIV infection often 
means ostracism, neglect, loss of family, abuse, or 
orphan status 2. 
In spite of the now estimated 40 million 
persons infected with HIV worldwide, no 
effective control has been done. There is universal 
agreement that ultimate control of HIV infection 
cannot occur until there is an effective 
preventative vaccine 3. 
 
ETIOLOGY 
The HIV-1 virus is an RNA virus related to the 
group of retroviruses. HIV-2 is another virus that 
causes a milder form of immunodeficiency in 
South and West Africa. The individual isolates of 
HIV from different persons vary a great deal. 
There is also considerable variation between 
sequential isolates from the same person. The virus 
always changes the antigenic structure of its outer 
coat. It spreads through syncitium formation of an 
infected cell with uninfected cells in vivo. The human 
virus is difficult to be cultured in animals except 
chimpanzee. It differs from the simian virus 4. 
 
Figure 1: Structure of HIV virus. (Cerveri et al, 1996)4. 
 
TRANSMISSION OF THE VIRUS 
In utero transmission 
The mechanism of in utero transmission is most 
likely through transplacental transmission of HIV, 
possibly enhanced by placental membrane 
inflammation that would increase the presence of 
infected maternal lymphocytes in the placenta and 
amniotic fluid or through maternofetal transfusion, 
especially following placental disruption. Direct 
evidence for in utero transmission comes from the 
finding that a small proportion of first-trimester and 
second-trimester abortuses from HIV-infected 
women have tissues infected with HIV. Several 
factors provide indirect evidence of in utero 
infection. The isolation of HIV from amniotic fluid 
supports the possibility of in utero infection. The 
consistent finding that a proportion of infected 
children already have HIV detectable in their 
peripheral blood at the time of delivery indicates that 
their infection occurred in utero at least several days 
before delivery, although mathematic modeling 
studies suggest that much of this in utero 
transmission occurs relatively late in gestation. Early, 
rapid disease progression in some infected children 
also suggests the possibility of early infection of 





Intrapartum transmission can occur through 
maternofetal transfusion of blood during labor or 
contact of infant skin or mucous membranes with 
the infected blood or other maternal secretions 
during delivery. Several pieces of evidence 
support the important role of intrapartum 
transmission. The small proportion of abortuses 
with evidence of HIV infection and the relatively 
small percentage (25%-40%) of infected children 
with evidence of HIV infection at birth suggest 
that more infections occur during the intrapartum 
period than before this time. Also, several of the 
important risk factors for infection (e.g., increased 
duration of membrane rupture or vaginal delivery) 
are specific to the intrapartum period. Finally, the 
substantial efficacy of some intrapartum 
interventions (e.g., elective cesarean section) 
support the importance of intrapartum 
transmission 6. 
Postpartum transmission through breast-feeding 
Infants born to mothers with HIV infection who 
escape infection during gestation and delivery 
may still become infected through breast-feeding. 
The rate of such infections is estimated at 12% to 
14%. Approximately, 29% of breast-fed infants of 
women who seroconvert following delivery 
contract HIV. 
HIV is commonly contained in the breast milk 
of HIV infected women. The mechanism of HIV 
transmission through breast-feeding is most likely 
the frequent and prolonged exposure of infant’s 
oral and gastrointestinal tracts to breast milk, but 
the actual unit of infection (i.e., cell free or cell 
associated) is unknown. Evidence for postpartum 
transmission from breast-feeding among women 
with chronic HIV infection comes from several 
studies in resource-rich and resource-poor 
settings. In addition, HIV transmission to breast-
fed children born to women who became infected 
after delivery through blood transfusion strongly 
supports transmission through this route 7. 
Risk factors for perinatal transmission of HIV 
are shown in table 18. 
Most (91%) of pediatric patients with AIDS 
acquired their infection through perinatal 
transmission, whereas 7% acquired HIV infection 
through receipt of contaminated blood or blood 
products. Cases of children who acquire HIV 




I- Immune system: 
(1)Thymitis. 
(2)Generalized lymphoproliferation with hyper-
gammaglobulinemia and B cell activation, 
decreased T helper cell number and reversed 
CD4: CD8 ratio. 
II-Opportunistic infections: Pneumocystis carinii, 
Candida, Mycobacterium avium intracellulare, 
herpes simplex virus, varicella zoster virus, 
cytomegalovirus, Epstein-Barr virus. 
Ill-Cardiovascular system: dilated cardiomyopathy, 
endocardial fibrosis. 
IV-Gastro-intestinal tract: enteropathy, 
malabsorption. 
V-Renal disease: Focal segmental glomerulosclerosis, 
mesangial proliferative glomerulosclerosis. 
VI-Central nervous system: Brain atrophy, brain 
malformation, brain infarction, encephalopathy. 
VII-Lungs: lymphocytic interstitial pneumonitis (LIP) 
(fig. 2). 
VIII-Hepatobiliary disease: fatty infiltration, portal 
inflammation, cholestasis, chronic active hepatitis, 
and virus C hepatitis. 
IX-Neoplastic: lymphoma, Kaposi's sarcoma, 
leiomyosarcoma. 
X-Skin: bacterial, viral and fungal infections, atopy, 
hypersensitivity, pruritic papular eruption. 
(Burns et al, 1997)9. 
 
 
Table 1. Risk factors for perinatal transmission of HIV. 
Clinical Advanced maternal HIV disease; illicit 
drug use during pregnancy; premature 
delivery <37 wk; breast-feeding 
Laboratory High viral load; low CD4+ count; 
anemia; low vitamin A levels in 
international settings 
Obstetric Duration of membrane rupture> 4 h; 
nonreceipt of C-section before onset of 
labor; chorioamnionitis; cervicovaginal 
infection; invasive procedures (e.g., 
amniocentesis); hemorrhage in labor. 




Figure 2. Lung biopsy showing LIP evident as mono-
morphic lymphoid infiltrate and an atypical mitotic 





Incubation period is 10 years in average in adults, 
less in children, due to immature immune system. 
The virus is actively destroying the immune 
system during the incubation period, but with no 
signs and symptoms. 
The majority of infected children are 
asymptomatic during the first 6 months of life. 
Common signs are failure to thrive, 
lymphadenopathy, splenomegaly, hepatomegaly 
and encephalopathy 10,11 (Table 2, fig. 3,4). 
 
 
Figure 3. Ulcerated Kaposi’s sarcoma on the sole12. 
 
 
Figure 4. Extensive eruption of herpes zoster on 
chest and shoulder12. 
 
Table(2). 1994 revised HIV pediatric classification 
system: clinical categories13. 
Category N: not symptomatic 
Children who have no signs or symptoms considered 
to be the result of HIV infection or who have only one 
of the conditions listed in category A 
Category A: mildly symptomatic 
Children with two or more of the conditions listed 
below but none of the conditions listed in categories 
Band C 
Lymphadenopathy (> 0.5 cm at more than two sites; 





Recurrent or persistent upper respiratory infection, 
sinusitis or otitis media 
Category B: moderately symptomatic 
Children who have symptomatic conditions other than 
those listed for category A or C to HIV infection. 
Examples of conditions in clinical category B include but 
are not limited to: 
Anemia (<8 gm/dl), neutropenia (<1000/mm3) or 
thrombocytopenia (<100 000/mm3). 
Bacterial meningitis, pneumonia, or sepsis (single 
episode) 
Candidiasis, oropharyngeal (thrush) persisting (>2 
months) in children > 6 months old 
Cardiomyopathy 
Cytomegalovirus infection, with onset before 1 month of 
age 
Diarrhea, recurrent or chronic 
Hepatitis 
Herpes simplex virus stomatitis, recurrent (more than 
two episodes within 1 year) 
Herpes simplex virus bronchitis, pneumonitis, or 
esophagitis with onset before 1 month of age 
Herpes zoster (shingles) involving at least two distinct 
episodes or more than one dermatome 
Leiomyosarcoma 
Lymphoid interstitial pneumonitis (LIP) or pulmonary 
lymphoid hyperplasia complex 
Nephropathy 
Nocardiosis 
Persistent fever (lasting > 1 month) 
Toxoplasmosis, onset before 1 month of age 
Varicella, disseminated (complicated chickenpox) 
Category C: severely symptomatic 
Children who have any condition listed in the 1987 
surveillance case definition for AIDS, with the exception 
of LIP (which is a category B condition) 
Serious bacterial infections, multiple or recurrent (i.e. 
any combination of at least two culture-confirmed 
infections within a 2-year period) of the following 
types: septicemia, pneumonia, meningitis, bone or joint 
infection, or abscess of an internal organ or body cavity 
(excluding otitis media, superficial skin or mucosal 
abscesses, and in-dwelling catheter-related infections) 
Candidiasis, esophageal or pulmonary (bronchi, trachea, 
lungs) 
Coccidioidomycosis, disseminated (at site other than or 
in addition to lungs or cervical or hilar lymph node) 
Cryptococcosis, extrapulmonary 
Cryptosporidiosis or isosporiasis with diarrhea persisting 
>1 month 
Cytomegalovirus disease with onset of symptoms at age 
>1 month (at a site other than liver, spleen, or lymph 
nodes) 
Encephalopathy (at least one of the following 
progressive findings present for at least 2 months in the 
absence of a concurrent illness other than HIV 
infection that could explain the findings): 1) failure to 
attain or loss of developmental milestones or loss of 
intellectual ability, verified by standard developmental 
scale or neuropsychological tests; 2) impaired brain 
growth or acquired microcephaly demonstrated by 
head circumference measurements or brain atrophy 
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demonstrated by CT or MRI (serial imaging is 
required for children <2 years of age); 3) acquired 
symmetric motor deficit manifested by two or more 
of the following: paresis, pathologic reflexes, 
ataxia, or gait disturbance 
Herpes simplex virus infection causing a 
mucocutaneous ulcer that persists for >1 month, or 
bronchitis, pneumonitis, or esophagitis for any 
duration affecting a child >1 month of age 
Histoplasmosis, disseminated (at a site other than or 
in addition to lungs or cervical or hilar lymph 
nodes) 
Kaposi's sarcoma  
Lymphoma, primary in brain 
Lymphoma, small, noncleaved cell (Burkitt’s), or 
immunoblastic or large cell lymphoma of B-cell or 
unknown immunologic abnormality 
 
DIAGNOSIS 14-17 
- CBC: thrombocytopenia, neutropenia, anemia. 
- Coagulation abnormalities with tendency to 
thrombosis. 
- Hypergammaglobulinemia. 
- Anti-HIV IgA: detected at 3-6 months of age. 
- Anti-HIV IgM: insensitive and nonspecific. 
- Anti-HIV IgG: passive maternal transfer, 
remains till 18 months of age. 
- Reversed CD4:CD8 ratio. 
- Culture, PCR if repeatedly negative till 6 
months of age then  do ELISA test: if 
positive  confirm by  Western blot test. 
[Early diagnosis is important for early 
initiation of therapy]. 
- Detection of P24, the major internal core protein 
of the virus. 
- Infants are considered to have in utero 
infection if virologic test results (HIV DNA or 
RNA or culture) are positive within 48 hours 
of life and subsequent results are also positive; 
because of the risk for contamination with 
maternal blood, cord blood samples typically 
are not recommended for diagnostic 
evaluations. 
- Infants are considered to have intrapartum HIV 
infection if diagnostic test results within the 
first 48 hours of life are negative but additional 
virologic testing after 1 week of life is positive 
in the absence of breast-feeding. 
 
PREVENTION 
Based on the current knowledge of the 
pathogenesis of perinatal HIV transmission, 
prevention can be focused in four areas: (1) 
reducing viral load, (2) reducing exposure to HIV 
during delivery, (3) preventing infection during or 
after exposure, and (4) reducing exposure to HIV 
during breast-feeding 18-20. 
Reducing Viral Load 
Viral load seems to be a predictor of in utero and 
intrapartum transmission. Moreover, decreasing viral 
load by antiretroviral therapy is effective in reducing 
the risk for transmission. 
Reducing Exposure of Fetus at Delivery 
During labor, infants are intensively exposed to HIV-
infected blood and cervicovaginal secretions of their 
mothers. Reducing the concentration of virus in 
blood and secretions and minimizing their contact 
with the skin and mucous membranes of the fetus is 
expected to reduce transmission risk. A short 
antenatal course of zidovudin (ZDV) begun at 36 
weeks’ gestation has been shown to reduce 
transmission risk by 50% in Thailand in a non-breast-
feeding group of HIV-infected women. The efficacy 
of this regimen was only 29% (95% confidence 
interval, 63-69%) for preventing in utero 
transmission but was 61% (95% confidence interval, 
19-82%) for preventing intrapartum transmission. 
Elective C-section has also been shown to 
significantly reduce transmission, but other 
intrapartum interventions alone have not shown 
efficacy. In two studies, in Malawi and Kenya, 
vaginal disinfection during labor and cleansing of 
neonates did not demonstrate an overall reduction in 
the risk for HIV transmission. 
Reducing the Risk for Infection If Exposed 
Evidence suggests that, when an infant has been 
exposed to HIV during labor and delivery, 
antiretroviral therapy given during or following 
exposure probably blocks infection in some cases. In 
animal models, postexposure prophylaxis has 
blocked retroviral infections. The use of ZDV as 
postexposure prophylaxis is thought to protect from 
infection following occupational exposure to HIV. 
Likewise, two clinical perinatal trials in Africa in 
which infants received prophylactic antiretrovirals 
(either ZDV-3TC or nevirapine) during labor and 
delivery and during the first week of life 
demonstrated the effectiveness of neonatal 
antiretroviral prophylaxis. 
Reducing Postpartum Exposure to HIV 
Infants born to HIV-infected mothers and who escape 
infection at birth are still at risk for infection if 
breast-fed by their mothers. A meta-analysis suggests 
that the incidence of infection in these children is 
approximately 3.2 infections per 100 child/year of 
breast-feeding among children more than 2.5 months 
old. A report by Miotti el al suggests a higher risk for 
transmission in the first 6 months of life compared 
with during the second year of life. The factors 




just beginning to be understood and include the 
presence or absence of detectable proviral HIV 
and RNA viral load in breast milk and 
immunologic factors, such as IgM levels in breast 
milk and secretory leukocyte protease inhibitor. 
Still unknown is whether cell-free or cell-
associated virus is the infectious unit of infection 
and whether colostrum or mature milk is more 
infectious. Also, infant-host factors, such as 
immunologic maturity, local mucosal factors in 
the mouth and gut that may affect transmission 
risk, and immunogenetic factors could affect the 
risk for infection of perinatally exposed children. 
 
TREATMENT 21-23 
(1) Antiviral drugs: 
a- Reverse transcriptase inhibitors 
• nucleoside   e.g.   azidothymidine  (zidovudine)   
60-180 mg/m2/6 hr IV, didanosine. 
•  non-nucleoside e.g. niverapine  
b- Protease inhibitors e.g. ritanovir. 
• Better use a combination e.g. HAART. (highly 
active anti-retroviral therapy) or pentatherapy. 
• Regimens should include zidovudine (the best 
one proved to prevent vertical transmission). 
• Early institution of therapy gives better results. 
(2) Opportunistic infections: 
-Pneumocystis carinii pneumonia 
Prevention oral 150 mg trimethoprim (TMP), 750 
mg sulfamethoxazole (SMZ)/m2/24h, as 2 daily 
doses for 3 consecutive days each week. 
 oral daily dapsone 
 monthly aerosolized or IV pentamidine 
TreatmentIV TMP/SMZ/6h with methyl-
prednisolone/6h for 5-7d, then orally for a total of 
21d. 
 IV pentamidine 
 TMP + dapsone orally 
 Respiratory support. 
-Antifungals for Candida or cryptococcal 
pneumonia. 
-Antimicrobials for mycobacteria, STD. 
-Prevention of atypical mycobacteria is through 
use of azithromycin 20 mg/kg orally once a 
week. 
-Prevention of TB is through regular tuberculin 
testing using 5IU of PPD every 2 year and every 
I year if there is contact with a case. 
-Antivirals of VZV, HSV, RSV and CMV. 
(3) Immunotherapy using IVIGs if there is hypo-
gammaglobulinemia (in 10% of cases) or history 
of recurrent bacterial infections. 
(4) Cytokine therapy : 
• Cytokines as hematological growth factors, e.g. 
erythropoietin, thrombopoietin, G-CSF, GM-CSF, 
IL-2, IL-3. 
• Interferons e.g. INF alpha as antibacterial INF 
gamma as antiviral 
• TNF inhibitors. 
(5) Immunizations: 
• Live attenuated virus vaccines are contraindicated, 
also for household contacts. 
• Live bacterial vaccines e.g. BCG are contraindicated 
except in a country with widespread TB infection, it 
can be given early before overt immunosuppression 
takes place. 
• Hib is given at 2, 4, 6 and 15 months of age. 
• Rotavirus vaccine: (controversy but some advise 
giving it at 2, 4, 6 months if no severe 
immunosuppression). 
• MMR and varicella vaccines: can be given at younger 
age before severe immnosuppression takes over, and 
be repeated after 3 months. 
• Pneumococcal vaccine is given at 2 years of age. 
• Influenza vaccine is to be given at 6 months and 
repeated yearly. 
• Vaccines given before HIV-related disease are no 
more effective and have to be repeated. 
The immunization schedule is shown in table 3. 
(6) General nutrition: failure to thrive is due to low 
birth weight together with poor intake due to 
anorexia. Enteropathy leads to chronic diarrhea and 
malabsorption. So, give high protein, micronutrient 
and calory nutrition through TPN or tube feeding. 
Breast-feeding is recommended in low 
socioeconomic classes to avoid gastroenteritis. 
(7) Others: 
- Treatment of other STD. 
- Treatment of the mother for HIV-infection. 
- Psychological and social support especially for 
orphans after death of one or both parents. 
- Pain relief and terminal care. 
- Ensure normal day care or school attendance. 
- Family health education. 
 
Table 3. Immunization of HIV-infected children. 
Immunization Schedule 
0BPoliomyelitis IPV: 2, 4, and 6-8 mo of age; 
booster 4-6 y of age 
OPV contraindicated 
Diphtheria 2, 4, 6, and 15-18 mo; booster 4-6 
y of age 
Pertussis 2, 4, 6 and 15-18 mo; booster 4-6 
y of age; whole cellular or 
acellular vaccine 
Tetanus 2, 4, 6, and 15-18 mo, booster 4-6 
y of age; then age 10 y and every 
10 y thereafter 
H. influenzae B 1, 4, 6, and 15-18 mo of age 
Hepatitis B 0, 1, and 6 mo of age if at risk for 
hepatitis B at birth; otherwise 
give at 6, 7, and 12 mo of age 
MMR 
 
12-15 mo, booster 4-6 y; 




Influenza Yearly, starting at 6 mo of age; 
first dose is followed by another 
dose 1 mo later; split vaccine is 
preferred 
Pneumococcal Polyvalent: 2 y of age; 1 booster 
5 y later; heptavalent; not 
established yet 
Varicella Considered only for children in 
category N1 or Al with an age-
specific CD4 % equal to or 
greater than 25% 
BCC Contraindicated except in 
developing countries 
(Laufer and Scott, 2000)10. 
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